<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769327</url>
  </required_header>
  <id_info>
    <org_study_id>CML0408</org_study_id>
    <secondary_id>GIMEMA-CML0408</secondary_id>
    <secondary_id>EUDRACT-2008-004384-19</secondary_id>
    <secondary_id>EU-20881</secondary_id>
    <nct_id>NCT00769327</nct_id>
  </id_info>
  <brief_title>Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia</brief_title>
  <acronym>CML0408</acronym>
  <official_title>Front-line Treatment of Philadelphia Positive (Ph Pos), BCRABL Positive, Chronic Myeloid Leukemia (CML) With Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imotinib) A Phase II Exploratory Multicentric Centre.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking
      some of the enzymes needed for cell growth.

      PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib
      mesylate works in treating patients with early chronic phase chronic myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the complete cytogenetic response rate at 12 months in patients with
           Philadelphia chromosome- and BCR-ABL-positive early chronic phase chronic myelogenous
           leukemia treated with nilotinib and imatinib mesylate.

      Secondary

        -  To assess the complete cytogenetic response rate at 6 and 24 months in these patients.

        -  To assess the major and complete molecular response rate at 6, 12, and 24 months in
           these patients.

        -  To assess the frequency and the types of BCR-ABL kinase domain mutations at 24 months
           during and for 3 years after study treatment.

        -  To assess the rate of failures and the time to failure at 12, 24, and 60 months in these
           patients.

        -  To assess compliance, toxicity, and adverse events in these patients.

        -  To understand the relationship between response, gene expression profile, biomarkers,
           and drug plasma concentrations in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral nilotinib twice daily in months 1-3, 7-9, 13-15, and 19-21 and oral
      imatinib mesylate once daily in months 4-6, 10-12, 16-18, and 22-24. Treatment continues for
      24 months in the absence of disease progression or unacceptable toxicity. Patients may be
      eligible to continue oral nilotinib and oral imatinib mesylate for up to another 36 months if
      it is in the interest of the patient.

      Blood samples and bone marrow biopsies are collected periodically for cytogenetic response by
      chromosome banding analysis and FISH analysis; real-time quantitative PCR mutational analysis
      and single nucleotide polymorphism analysis of BCR-ABL transcripts; and gene expression
      profiling and correlative biomarker studies.

      After completion of study therapy, patients are followed every 6 months for 3 years and then
      every 12 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cytogenetic response rate</measure>
    <time_frame>At 12 months from study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete cytogenetic response</measure>
    <time_frame>At at 6 and 24 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and complete molecular response rate</measure>
    <time_frame>At at 6, 12 and 24 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of BCR-ABL kinase domain mutations (number, timing, and type)</measure>
    <time_frame>At at 24 months during and for 3 years after study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of failures and the time to failure</measure>
    <time_frame>At 12, 24, and 60 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>At 24 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and type of adverse events (AE) and severe AE</measure>
    <time_frame>At 24 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between response, the gene expression profile, the biomarkers of leukemic cells, and plasma concentrations of nilotinib and imatinib mesylate</measure>
    <time_frame>At 24 months from study entry</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">129</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Cytologically and cytogenetically confirmed chronic myelogenous leukemia meeting the
             following criteria:

               -  Early chronic phase disease (&lt; 6 months from diagnosis)

               -  Philadelphia chromosome-positive disease

               -  BCR-ABL-positive

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  ALT and AST = 2.5 times upper limit of normal (ULN) (5.0 times ULN if considered due
             to leukemia)

          -  Alkaline phosphatase = 2.5 times ULN (unless considered due to leukemia)

          -  Serum bilirubin = 1.5 times ULN

          -  Serum creatinine = 1.5 times ULN

          -  Serum amylase = 1.5 times ULN

          -  Serum lipase = 1.5 times ULN

          -  Normal serum levels of the following or correctable with supplements:

               -  Potassium

               -  Total calcium (corrected for serum albumin)

               -  Magnesium

               -  Phosphorus

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier method contraception during study and for
             up to 3 months following completion of study treatment

          -  No impaired cardiac function, including any of the following:

               -  LVEF &lt; 45% by MUGA scan or echocardiogram

               -  Uncontrolled congestive heart failure

               -  Uncontrolled hypertension

               -  Uncontrolled angina pectoris

               -  Myocardial infarction within the past 12 months

          -  No significant electric heart abnormalities, including any of the following:

               -  History or active ventricular or atrial tachyarrhythmias

               -  Congenital long QT syndrome and/or QTc &gt; 450 msec on screening ECG

          -  No history of acute (within one year) or chronic pancreatitis

          -  No impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of study drugs (e.g., ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

          -  No acute or chronic liver or renal disease considered unrelated to leukemia

          -  No known diagnosis of HIV infection

          -  No other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
             diabetes, active or uncontrolled infection) that could cause unacceptable safety risks
             or compromise compliance with the protocol

          -  No other primary malignancy that is currently clinically significant or requires
             active intervention

        PRIOR CONCURRENT THERAPY:

          -  More than 2 weeks since prior major surgery and recovered

          -  More than 30 days since prior imatinib mesylate, with a washout period of ≥ 7 days

          -  More than 4 weeks since prior investigational drug

          -  No prior hematopoietic stem cell transplantation

          -  No concurrent therapeutic coumarin derivates (i.e., warfarin, acenocoumarol,
             phenprocoumon)

          -  No concurrent medications that would prolong the QT interval

          -  No concurrent chemotherapy, investigational agents, radiotherapy, or biologic therapy

          -  Prior treatment with hydroxyurea or anagrelide allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Baccarani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Italiano Malattie EMatologiche dell'Adulto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Alessandria</name>
      <address>
        <city>Alessandria</city>
        <zip>I-15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Area Medica P.O.</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.G. Moscati Hospital</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia 1 - Università degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist.Ematologia e Oncologia Medica L.e A. Seragnoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità di Oncoematologia Azienda Ospedaliera Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - DiMI - Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Università degli Studi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Martina di Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez. di medicina Interna Oncologia ed Ematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtià degli Studi di Napoli &quot;Federico II&quot; - Facoltà di medicina e chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità operativa complessa di Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia, Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDO Ematologia 2 AOU S.Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G. B. Rossi - Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

